LY2456302 is a novel, potent, orally-bioavailable small molecule kappa-selective antagonist with activity in animal models predictive of efficacy in mood and addictive disorders.
Abstract Kappa opioid receptors and their endogenous neuropeptide ligand, dynorphin A, are densely localized in limbic and cortical areas comprising the brain reward system, and appear to play a key role in modulating stress and mood. Growing literature indicates that kappa receptor antagonists may be beneficial in the treatment of mood and addictive disorders. However, existing literature on kappa receptor antagonists have used extensively JDTic and nor-BNI which exhibit long-lasting pharmacokinetic properties that complicate experimental design and interpretation of results. Herein, we report for the first time ...
Source: Neuropharmacology - September 23, 2013 Category: Drugs & Pharmacology Authors: Rorick-Kehn LM, Witkin JM, Statnick MA, Eberle EL, McKinzie JH, Kahl SD, Forster BM, Wong CJ, Li X, Crile RS, Shaw DB, Sahr AE, Adams BL, Quimby SJ, Diaz N, Jimenez A, Pedregal C, Mitch CH, Knopp KL, Anderson WH, Cramer JW, McKinzie DL Tags: Neuropharmacology Source Type: research

Effects of prolonged selective serotonin reuptake inhibition on the development and expression of L-DOPA-induced dyskinesia in hemi-parkinsonian rats.
Abstract Dopamine (DA) replacement therapy with L-DOPA is the standard treatment for Parkinson's disease (PD). Unfortunately chronic treatment often leads to the development of abnormal involuntary movements (AIMs) referred to as L-DOPA-induced dyskinesia (LID). Accumulating evidence has shown that compensatory plasticity in serotonin (5-HT) neurons contributes to LID and recent work has indicated that acute 5-HT transporter (SERT) blockade provides anti-dyskinetic protection. However neither the persistence nor the mechanism(s) of these effects have been investigated. Therefore the current endeavor sought to mimi...
Source: Neuropharmacology - September 22, 2013 Category: Drugs & Pharmacology Authors: Conti MM, Ostock CY, Lindenbach D, Goldenberg AA, Kampton E, Dell'isola R, Katzman AC, Bishop C Tags: Neuropharmacology Source Type: research

Predicting relapse in major depressive disorder using patient-reported outcomes of depressive symptom severity, functioning, and quality of life in the individual burden of illness index for depression (IBI-D)
This study examines the utility of a single multidimensional measure that captures variance in patient-reported Depressive Symptom Severity, Functioning, and Quality of Life (QOL), in predicting MDD relapse.Methods: Complete data from remitted patients at the completion of 12 weeks of citalopram in the STAR*D study were used to calculate the Individual Burden of Illness index for Depression (IBI-D), and predict subsequent relapse at six (n=956), nine (n=778), and twelve months (n=479) using generalized linear models.Results: Depressive Symptom Severity, Functioning, and QOL were all predictors of subsequent relapse. Using ...
Source: Journal of Affective Disorders - September 16, 2013 Category: Neurology Authors: Waguih William IsHak, Jared M. Greenberg, Robert M. Cohen Tags: Research reports Source Type: research

Selective serotonin reuptake inhibitor (SSRI) toxicosis in cats: 33 cases (2004–2010)
ConclusionsThe prognosis for SSRI ingestion in this population of cats was excellent. Decontamination and supportive care for at least 12–24 hours can be considered in cats with SSRI ingestion, particularly venlafaxine to monitor resolution of clinical signs. (Source: Journal of Veterinary Emergency and Critical Care)
Source: Journal of Veterinary Emergency and Critical Care - September 9, 2013 Category: Veterinary Research Authors: Cassandra M. Pugh, Joseph T. Sweeney, Christopher P. Bloch, Justine A. Lee, Justine A. Johnson, Lynn R. Hovda Tags: Retrospective Study Source Type: research

Predicting relapse in major depressive disorder using patient-reported outcomes of depressive symptom severity, functioning, and quality of life in the individual burden of illness index for depression (IBI-D)
This study examines the utility of a single multidimensional measure that captures variance in patient-reported Depressive Symptom Severity, Functioning, and Quality of Life (QOL), in predicting MDD relapse.Methods: Complete data from remitted patients at the completion of 12 weeks of citalopram in the STAR*D study were used to calculate the Individual Burden of Illness index for Depression (IBI-D), and predict subsequent relapse at six (n=956), nine (n=778), and twelve months (n=479) using generalized linear models.Results: Depressive Symptom Severity, Functioning, and QOL were all predictors of subsequent relapse. Using ...
Source: Journal of Affective Disorders - September 7, 2013 Category: Neurology Authors: Waguih William IsHak, Jared M. Greenberg, Robert M. Cohen Tags: Research reports Source Type: research

Histological changes in the liver of fetuses of pregnant rats following citalopram administration
Conclusion: This study showed that citalopram administration during gestation may have some adverse effects on the phagocytic cell population in the fetal liver of rats. (Source: Indian Journal of Pharmacology)
Source: Indian Journal of Pharmacology - September 6, 2013 Category: Drugs & Pharmacology Authors: Zeynab MohammadiMahnaz AzarniaGhadireh MirabolghasemiAbdolhossein ShiraviZohreh Mohammadi Source Type: research

Serotonin syndrome under combination of linezolid and low‐dose citalopram with amiodarone
(Source: Psychiatry and Clinical Neurosciences)
Source: Psychiatry and Clinical Neurosciences - September 2, 2013 Category: Neuroscience Authors: Jinling Ma, Ping Zhu, Guohong Tu, Xiaoqian Li Tags: Letter to the Editor Source Type: research

Estimation of CYP2D6*10 genotypes on citalopram disposition in Chinese subjects by population pharmacokinetic assay
Summary What is known and objectiveThere is great interindividual variability in citalopram (CIT) pharmacokinetics. We attempted to establish a population pharmacokinetic (PPK) model of CIT in Chinese healthy subjects, to evaluate the effect of genetic polymorphism on CIT pharmacokinetics and to compare the PPK and non‐compartmental (NCA) assays in the estimation of CIT bioequivalence. MethodsBlood samples of 23 healthy subjects were collected after administration of CIT; plasma concentration of CIT was analysed using LC/MS‐MS. CYP2C19 and CYP2D6*10 genotypes were determined. PPK model was established by using nonlinea...
Source: Journal of Clinical Pharmacy and Therapeutics - August 28, 2013 Category: Drugs & Pharmacology Authors: B. Chen, Y. Xu, T. Jiang, R. Feng, J. Sun, W. Zhang, W. Yang, J. Li, O. Adeniyi, H. Chen Tags: Original Article Source Type: research

SLC6A4 Polymorphisms and Age of Onset in Late-life Depression on Treatment Outcomes with Citalopram: A Sequenced Treatment Alternatives to Relieve Depression (STAR*D) Report.
CONCLUSIONS: Variants in the indel promoter region of the SLC6A4 gene have a more robust effect to antidepressant outcome among older subjects who experienced their first MDE at a later age. The mechanism of action of these variants remains to be determined. PMID: 23973251 [PubMed - as supplied by publisher] (Source: The American Journal of Geriatric Psychiatry)
Source: The American Journal of Geriatric Psychiatry - August 27, 2013 Category: Psychiatry Tags: Am J Geriatr Psychiatry Source Type: research

Selective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD).
CONCLUSIONS: There is no evidence of effect of SSRIs in children and emerging evidence of harm. There is limited evidence of the effectiveness of SSRIs in adults from small studies in which risk of bias is unclear. PMID: 23959778 [PubMed - as supplied by publisher] (Source: Cochrane Database of Systematic Reviews)
Source: Cochrane Database of Systematic Reviews - August 20, 2013 Category: Journals (General) Authors: Williams K, Brignell A, Randall M, Silove N, Hazell P Tags: Cochrane Database Syst Rev Source Type: research

Nocturnal Anxiety in a Youth with Rapid-onset Obesity, Hypothalamic Dysfunction, Hypoventilation, and Autonomic Dysregulation (ROHHAD).
CONCLUSIONS: Core symptoms of ROHHAD may precipitate psychiatric disorders. A systematic evidence-based approach to psychopharmacology is necessary in the setting of psychiatric consultation. PMID: 23970913 [PubMed] (Source: Journal of the Canadian Academy of Child and Adolescent Psychiatry)
Source: Journal of the Canadian Academy of Child and Adolescent Psychiatry - August 1, 2013 Category: Psychiatry Authors: Grudnikoff E, Foley C, Poole C, Theodosiadis E Tags: J Can Acad Child Adolesc Psychiatry Source Type: research

Citalopram and levosulpiride: a dangerous drug combination for QT prolongation
We report the case of an 89-year-old female patient who presented to the emergency department after out-of-hospital cardiac arrest due to polymorphic ventricular tachycardia treated by public access defibrillation. The admission electrocardiogram (ECG) showed extreme QT prolongation (650 milliseconds) with recurrent episodes of nonsustained polymorphic ventricular tachycardia. Intravenous magnesium sulfate therapy was instituted. After history taking, it was found that the patient was on citalopram and that, 2 days prior to admission, she had begun treatment with levosulpiride. This drug combination resulted in marked prol...
Source: The American Journal of Emergency Medicine - July 29, 2013 Category: Emergency Medicine Authors: Sergio Agosti, Laura Casalino, Giovanni Bertero, Alessandro Burrone, Claudio Brunelli, Silvana Morelloni Tags: Case Reports Source Type: research

Citalopram suppresses thymocyte cytokine production
Abstract: Antidepressant drugs, in particular those targeting the serotonin (5-HT)-reuptake system via the serotonin transporter (5-HTT), are known to exhibit antiinflammatory properties and have demonstrated therapeutic efficacy in rodent models of autoimmune disease like experimental autoimmune encephalomyelitis or experimental rheumatoid arthritis. A crucial difference between animal models and the actual human autoimmune disease is the fact that in animals predominantly induced T cells are studied after sensitization with autoantigen. In humans, however, naturally occurring cytokine-producing T cells might play a signi...
Source: Journal of Neuroimmunology - July 24, 2013 Category: Allergy & Immunology Authors: Aparna R. Shenoy, Thomas Dehmel, Mark Stettner, David Kremer, Bernd C. Kieseier, Hans Peter Hartung, Harald H. Hofstetter Tags: Research Papers Source Type: research

Cardiotoxicity in a Citalopram and Olanzapine Overdose
Conclusions: This case describes cardiotoxicity directly correlated with supratherapeutic citalopram levels in overdose. (Source: The Journal of Emergency Medicine)
Source: The Journal of Emergency Medicine - July 22, 2013 Category: Emergency Medicine Authors: Derrick D. Lung, Alan H.B. Wu, Roy R. Gerona Tags: Selected Topics: Toxicology Source Type: research

Patient‐reported outcomes of quality of life, functioning, and depressive symptom severity in major depressive disorder comorbid with panic disorder before and after ssri treatment in the star*d trial
ConclusionsFunctional outcomes using QOL and functioning measures should be utilized in treating and researching MDD so that shortfalls in traditional treatment can be identified and additional interventions can be designed to address severe baseline QOL and functioning deficits in MDD comorbid with PD. (Source: Depression and Anxiety)
Source: Depression and Anxiety - July 16, 2013 Category: Psychiatry Authors: Waguih William IsHak, James Mirocha, Scott Christensen, Fan Wu, Richard Kwock, Joseph Behjat, Sarah Pi, Araks Akopyan, Eric D. Peselow, Robert M. Cohen, David Elashoff Tags: Research Article Source Type: research

Effects of citalopram and escitalopram on fMRI response to affective stimuli in healthy volunteers selected by serotonin transporter genotype
This study was designed to assess whether functional magnetic resonance imaging (fMRI) following antidepressant administration (pharmaco-fMRI) is sufficiently sensitive to detect differences in patterns of activation between enantiomers of the same compound. Healthy adult males (n=11) participated in a randomized, double-blind, cross-over trial with three medication periods during which they received citalopram (racemic mixture), escitalopram (S-citalopram alone), or placebo for 2 weeks. All participants had high expression serotonin transporter genotypes. An fMRI scan that included passive viewing of overt and covert affe...
Source: Psychiatry Research: Neuroimaging - July 11, 2013 Category: Psychiatry Authors: Michael E. Henry, Tara L. Lauriat, Steven B. Lowen, Jeffrey H. Churchill, Colin A. Hodgkinson, David Goldman, Perry F. Renshaw Tags: Functional magnetic resonance imaging Source Type: research

Table of Contents
Abstract Use of valproate while pregnant increases child's autism risk SSRI exposure in utero linked to autism in children Pneumonia risk associated with typical versus atypical antipsychotics in nursing home residents Results conflict with FDA warning on high‐dose citalopram Risk of Clostridium difficile infection with antidepressants? Editor's Commentary: DSM‐5: Implications for psychopharmacology Benzodiazepine augmentation does not improve schizophrenia symptoms Bupropion effective for smoking treatment nonresponders Aripiprazole once‐monthly assessed for schizophrenia d‐Cycloserine augments CBT for social anxi...
Source: The Brown University Psychopharmacology Update - July 9, 2013 Category: Psychiatry Source Type: research

Implementing an antidepressant treatment strategy for post-MI depression does not reduce risk of further cardiovascular events or mortality
Question Question: Does antidepressant treatment of postmyocardial infarction (MI) depression reduce risk of further cardiovascular events or mortality compared with usual care? Patients: In total, 331 adults diagnosed with International Classification of Diseases 10th Edition (ICD-10) depression between 3 and 12 months post-MI. Initial screening was through the use of Beck Depression Inventory administered at baseline, 3, 6, 9 and 12 months post-MI. Exclusions: current treatment of depression; other diseases likely to influence long-term survival; communication difficulties or inability to participate in follow-...
Source: Evidence-Based Mental Health - July 9, 2013 Category: Psychiatry & Psychology Authors: Davidson, K. W., Burg, M. M. Tags: Clinical trials (epidemiology), Epidemiologic studies, Depressive disorder, Epidemiology, Screening (epidemiology) Therapeutics Source Type: research

Higher dose L-methylfolate may be an effective adjunctive therapy for adults with major depression who have inadequate response to SSRIs
Question Question: In adults with major depression who have had a partial or non-response to selective serotonin reuptake inhibitors (SSRIs), is the addition of l-methylfolate effective? Patients: 148 adults (trial 1) and 75 adults (trial 2) with Diagnostic Statistical Manual of Mental Disorders - IV (DSM-IV) major depressive disorder who had not responded to at least 8 weeks adequate treatment with an SSRI (≥20 mg/day of fluoxetine, citalopram or paroxetine; ≥10 mg/day escitalopram; or ≥50 mg/day of sertraline). Exclusion criteria: pregnancy, breastfeeding or being of child-bearing age and not...
Source: Evidence-Based Mental Health - July 9, 2013 Category: Psychiatry & Psychology Authors: Roberts, S. H., Tranter, R. Tags: Clinical trials (epidemiology), Neurology, Depressive disorder, Epidemiology, Screening (epidemiology) Therapeutics Source Type: research

Adding antidepressants to antipsychotics for treatment of subsyndromal depressive symptoms in schizophrenia: Impact on positive and negative symptoms.
CONCLUSIONS: In patients with schizophrenia/schizoaffective disorder, treating depressive symptoms with citalopram appears to carry the added benefit of improving negative symptoms. PMID: 23825848 [PubMed - in process] (Source: Indian Journal of Psychiatry)
Source: Indian Journal of Psychiatry - July 5, 2013 Category: Psychiatry Tags: Indian J Psychiatry Source Type: research

Review of treatment for late-life depression [Articles]
We present an evidence-based review of treatment for late-life depression, focusing on pharmacological approaches, including monotherapy, combination and augmentation strategies. Selective serotonin reuptake inhibitors such as sertraline and citalopram are well tolerated, have the advantage of a favourable side-effect profile, and are good options for first-line treatment. Second-line treatment options include combination therapy with a second antidepressant, or treatment augmentation with an antipsychotic or lithium. We also consider evidence for non-pharmacological treatment strategies, including psychological therapy an...
Source: Advances in Psychiatric Treatment - July 1, 2013 Category: Psychiatry Authors: Allan, C. L., Ebmeier, K. P. Tags: Articles Source Type: research

Treatment of depression in type 2 diabetic patients: Effects on depressive symptoms, quality of life and metabolic control
Conclusions: Treating depressive symptoms with medical therapy in T2DM is associated with improvements in QoL and depression, but with no improvement in metabolic control or weight. (Source: Diabetes Research and Clinical Practice)
Source: Diabetes Research and Clinical Practice - June 24, 2013 Category: Endocrinology Authors: Joana Nicolau, Rosmeri Rivera, Carla Francés, Begoña Chacártegui, Lluís Masmiquel Tags: Clinical Care and Education Source Type: research

Majority of Americans on prescription drugs, study says
Billions of dollars are spent on prescription drugs each year, and new research out of the Mayo Clinic shows nearly 70 percent of Americans are on at least one prescription drug — and more than half are on two. I previously reported Americans took a record number of prescription drugs last year — 4.02 billion prescriptions in 2011, up from 3.99 billion in 2010 — at a cost of $308.6 billion, with antidepressants Xanax, Celexa and Zoloft among the most prescribed. Seventeen percent of the patients… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - June 20, 2013 Category: Pharmaceuticals Authors: Bayan Raji Source Type: research

How to combine non-compartmental analysis with the population pharmacokinetics? A study of tobacco smoke's influence on the bioavailability of racemic citalopram in rats.
Conclusions: A tobacco smoke slows down the absorption of the CIT and at the same time makes it more effective. The consistency of results obtained both with NCA and NLME decreased the risk of model misspecification and increased confidence in the final conclusions. Combining NLME with NCA may therefore be recommended for investigating pharmacokinetic properties of the drug in the sparse designs. PMID: 23744437 [PubMed - in process] (Source: Pharmacological Reports)
Source: Pharmacological Reports - June 12, 2013 Category: Drugs & Pharmacology Authors: Jawień W, Majcherczyk J, Kulza M, Florek E, Piekoszewski W Tags: Pharmacol Rep Source Type: research

NK1 receptor antagonism lowers occupancy requirement for antidepressant-like effects of SSRIs in the Gerbil forced swim test.
Abstract The known interactions between the serotonergic and neurokinin systems suggest that serotonin reuptake inhibitor (SSRIs) efficacy may be improved by neurokinin-1 receptor (NK1R) antagonism. In the current studies combination of a subeffective dose of an SSRI (0.3 mg/kg fluoxetine or 0.03 mg/kg citalopram) with a subeffective dose of an NK1R antagonist (0.3 mg/kg aprepitant or 1 mg/kg CP-122,721) produced efficacy in the gerbil forced swim test (FST). Serotonin transporter (SERT) occupancy produced by 1 mg/kg fluoxetine (lowest efficacious dose) was 52 ± 5% and was...
Source: Neuropharmacology - June 12, 2013 Category: Drugs & Pharmacology Authors: Lelas S, Li YW, Wallace-Boone T, Taber MT, Newton A, Pieschl R, Davis CD, Molski T, Newberry K, Parker MF, Gillman K, Bronson JJ, Macor JE, Lodge NJ Tags: Neuropharmacology Source Type: research

Major depression after withdrawing dopamine agonists in two patients with restless legs syndrome and impulse control disorders
An 84-year-old man with no psychiatric history had a multifactorial (i.e., family history, renal insufficiency, sensory distal polyneuropathy) case of restless legs syndrome (RLS) of 20years’ duration. Gabapentin and codeine did not improve RLS but bromocriptine, then pramipexole 0.7mg did. Because he developed augmentations and impulse control disorders (ICD) (e.g., teleshopping of antique books, sexual advances to his niece), we switched him from pramipexole to fentanyl overnight, which alleviated RLS symptoms. Three weeks later, he began to feel deeply sad and apathetic; he experienced a loss of interest and pleas...
Source: Sleep Medicine - May 28, 2013 Category: Sleep Medicine Authors: Claire Launois, Smaranda Leu-Semenescu, Agnès Brion, Isabelle Arnulf Tags: Letters to the Editor Source Type: research

Prescribe Escitalopram Instead of Citalopram
I would like to respond to the recently published review entitled “Citalopram, QTc Interval Prolongation, and Torsade de Pointes. How Should We Apply the Recent FDA Ruling?” A revised Drug Safety Communication on Celexa was posted on the US Food and Drug Administration (FDA) Web site on March 28, 2012, which included data obtained from randomized double-blind placebo-controlled cross-over studies of the effects of citalopram and escitalopram on the corrected QT [QTc] intervals in adults. Citalopram 20 mg caused an average QTc prolongation of 8.5 ms (95% confidence interval [CI], 6.2-10.8 ms), while the therapeu...
Source: The American Journal of Medicine - May 24, 2013 Category: Journals (General) Authors: David L. Keller Tags: Letters Source Type: research

The Reply
As Keller noted, both citalopram and escitalopram cause dose-dependent QTc-interval prolongation, greater for citalopram than escitalopram. The threshold for clinical significance of the QTc interval is an absolute duration of>500 ms or a change from baseline of>60 ms. Data cited to support the warnings issued do not specify whether any subjects exceeded these clinically significant thresholds. (Source: The American Journal of Medicine)
Source: The American Journal of Medicine - May 24, 2013 Category: Journals (General) Authors: W. Victor R. Vieweg, Mehrul Hasnain, Robert H. Howland Tags: Letters Source Type: research

Systematic Toxicological Analysis Revealing a Rare Case of Captan Ingestion.
This article presents a case of suicide by intoxication with various pharmaceuticals, particularly anticonvulsants, combined with the fungicide captan. A cause of death could not be ascertained at autopsy. However, systematic toxicological analysis (STA) including a screening via solid-phase microextraction (SPME) and gas chromatography-mass spectrometry (GC-MS) for (semi) volatile organic compounds revealed results suggesting a possible cause of death. The effects of captan on the human organism, its metabolism, and distribution will be discussed. Macroscopically, the cause of death was unascertained. STA revealed clonaze...
Source: Journal of Forensic Sciences - May 21, 2013 Category: Forensic Medicine Authors: Gottzein AK, Musshoff F, Madea B Tags: J Forensic Sci Source Type: research

Is it possible to evaluate true prophylactic efficacy of antidepressants in severely ill patients with recurrent depression? Lessons from a placebo-controlled trial. The fifth trial of the Danish University Antidepressant Group (DUAG-5)
Conclusions: The high risk of drop out prior to randomisation among the eligible patients was presumably caused by an interaction between the study design and the study population. The findings suggest that long-term trial designs interposing a drug-free period prior to randomisation are not feasible and recommendable in severely ill patients. (Source: Journal of Affective Disorders)
Source: Journal of Affective Disorders - May 15, 2013 Category: Neurology Authors: Rasmus W. Licht, on behalf of the Danish University Antidepressant Group Tags: Research reports Source Type: research

Evaluation of the FDA Warning Against Prescribing Citalopram at Doses Exceeding 40 mg.
CONCLUSIONS This large study found no elevated risks of ventricular arrhythmia or all-cause, cardiac, or noncardiac mortality associated with citalopram dosages >40 mg/day. Higher dosages were associated with fewer adverse outcomes, and similar findings were observed for a comparison medication, sertraline, not subject to the FDA warning. These results raise questions regarding the continued merit of the FDA warning. PMID: 23640689 [PubMed - as supplied by publisher] (Source: The American Journal of Psychiatry)
Source: The American Journal of Psychiatry - May 3, 2013 Category: Psychiatry Authors: Zivin K, Pfeiffer PN, Bohnert AS, Ganoczy D, Blow FC, Nallamothu BK, Kales HC Tags: Am J Psychiatry Source Type: research

The nervous and prenervous roles of serotonin in Echinococcus spp.
it MC Abstract Serotonin (5-hydroxytryptamine, 5-HT) is an important neuroactive and morphogenetic molecule in several metazoan phyla, including flatworms. Serotoninergic nervous system studies are incomplete and 5-HT function/s are unknown in Echinococcus spp., the flatworm parasites that cause hydatid disease. In the present work, we searched for genes of the serotoninergic pathway and performed immunocytochemical and functional analyses of 5-HT in Echinococcus spp. Bioinformatic analysis using the recently available Echinococcus multilocularis and Echinococcus granulosus genomes suggests the presence of genes e...
Source: International Journal for Parasitology - April 29, 2013 Category: Parasitology Authors: Camicia F, Herz M, Prada LC, Kamenetzky L, Simonetta SH, Cucher MA, Bianchi JI, Fernández C, Brehm K, Rosenzvit MC Tags: Int J Parasitol Source Type: research

Table of Contents
Abstract PATS follow‐up study shows persistence of ADHD symptoms in young children New CDC data on ADHD shows increase in diagnosis, raises questions Is there a role for amantadine and memantine in pervasive developmental disorders? Intranasal oxytocin for boys with autism shows promise Atypicals: Mixed results for treating PDD Polymorphisms and response to citalopram in children DSM‐5 to include PTSD for preschoolers National survey looks at psychotropic drug use in teens Risperidone and iron deficiency in pediatric patients Treating pediatric bipolar depression Aricept packaging change “Love Rider” contai...
Source: The Brown University Child and Adolescent Psychopharmacology Update - April 19, 2013 Category: Psychiatry Source Type: research

Combined NK1 antagonism and serotonin reuptake inhibition: effects on emotional processing in humans
Conclusions: These results suggest that acute administration of GSK424887 modulated some aspects of emotional processing but these effects were not similar to those seen previously with antidepressant agents. This was the first use of the battery of emotional processing tasks in a Phase 1 study. Repeated administration of the test and active control drugs may be needed to reliably characterise their effects. (Source: Journal of Psychopharmacology)
Source: Journal of Psychopharmacology - April 19, 2013 Category: Psychiatry Authors: Harmer, C. J., Dawson, G. R., Dourish, C. T., Favaron, E., Parsons, E., Fiore, M., Zucchetto, M., Bifone, A., Poggesi, I., Fernandes, S., Alexander, R. C., Goodwin, G. M. Tags: Original Papers Source Type: research

Paradoxical effects of short-term antidepressant treatment in fMRI emotional processing models in volunteers with high neuroticism.
CONCLUSIONS: These results suggest that 7 days of SSRI administration can increase neural markers of fear reactivity in subjects at the high end of the N dimension and may be related to early increases in anxiety and agitation seen early in treatment. Such processes may be involved in the later therapeutic effects through decreased avoidance and increased learning about social 'threat' cues. PMID: 23597109 [PubMed - as supplied by publisher] (Source: Psychological Medicine)
Source: Psychological Medicine - April 19, 2013 Category: Psychiatry Authors: Di Simplicio M, Norbury R, Reinecke A, Harmer CJ Tags: Psychol Med Source Type: research

Review: short-term benefit of escitalopram versus citalopram for depression uncertain, but big difference in French health insurance costs
Question Question: What is the efficacy of citalopram compared with escitalopram (its chiral switch form) in people with depression, and what is the impact on health insurance costs? Outcomes: Efficacy (response to treatment defined as 50% decrease in depression score on the Montgomery-Åsberg depression rating scale or Hamilton Scale) at 8 weeks (or closest time point); treatment acceptability (proportion of patients not dropping out during treatment); health insurance costs. Methods Design: Systematic review with meta-analysis. Data sources: A systematic review of reviews and randomised controlled trials (RCTS)...
Source: Evidence-Based Mental Health - April 12, 2013 Category: Psychiatry & Psychology Authors: Cipriani, A., Barbui, C. Tags: Clinical trials (epidemiology), Depressive disorder, Epidemiology Therapeutics Source Type: research

Increase in Work Productivity of Depressed Individuals With Improvement in Depressive Symptom Severity.
CONCLUSIONS Patients with clinically significant reductions in symptom severity during initial treatment were more likely than nonresponders to experience significant improvements in work productivity. In contrast, patients who achieved symptom remission in second-step treatment continued to have impairment at work. Patients who have demonstrated some degree of treatment resistance are more prone to persistent impairment in occupational productivity, implying a need for additional, possibly novel, treatments. PMID: 23558394 [PubMed - as supplied by publisher] (Source: The American Journal of Psychiatry)
Source: The American Journal of Psychiatry - April 5, 2013 Category: Psychiatry Authors: Trivedi MH, Morris DW, Wisniewski SR, Lesser I, Nierenberg AA, Daly E, Kurian BT, Gaynes BN, Balasubramani GK, Rush AJ Tags: Am J Psychiatry Source Type: research

Inhibition of Glycine Transporter-I as a Novel Mechanism for the Treatment of Depression
Conclusions: Our preliminary findings suggest that enhancing NMDA function can improve depression-like behaviors in rodent models and in human depression. Establishment of glycine transporter-I inhibition as a novel treatment for depression waits for confirmation by further proof-of-principle studies. (Source: Biological Psychiatry)
Source: Biological Psychiatry - April 4, 2013 Category: Psychiatry Authors: Chih-Chia Huang, I-Hua Wei, Chieh-Liang Huang, Kuang-Ti Chen, Mang-Hung Tsai, Priscilla Tsai, Rene Tun, Kuo-Hao Huang, Yue-Cune Chang, Hsien-Yuan Lane, Guochuan Emil Tsai Tags: Archival Reports Source Type: research

Typical Clinical Findings Should Prompt Investigation for Juvenile Huntington Disease
An 11-year-old boy presented for neurological evaluation with a 5-year history of global developmental regression, abnormal involuntary movements, and worsening behavioral problems. He was adopted at 14 months of age and there was limited prenatal or family history. In early childhood, he had appropriate gross motor, fine motor, and language development, but “shakiness” was noted by his adoptive parents. In first grade, he was able to ride a bicycle, participate in gym class, dress himself, use utensils, write in cursive, and read at grade level. Since that time, a slow regression of fine motor, gross motor, an...
Source: Pediatric Neurology - April 1, 2013 Category: Neurology Authors: Priya Monrad, Deborah L. Renaud Tags: Images in Child Neurology Source Type: research

Serotonergic and adrenergic drug interactions associated with linezolid: a critical review and practical management approach.
CONCLUSIONS: Linezolid-associated serotonergic drug interactions occur more commonly than adrenergic interactions. Serotonergic interactions considered probable according to the Horn Drug Interaction Probability Scale do not appear to correlate with drug dosage; time of onset ranges from
Source: The Annals of Pharmacotherapy - April 1, 2013 Category: Drugs & Pharmacology Authors: Ramsey TD, Lau TT, Ensom MH Tags: Ann Pharmacother Source Type: research

Pharmacogenomic predictors of citalopram treatment outcome in major depressive disorder.
Conclusions. These findings point to SMAD7 and SIGLECP3 as candidate predictive biomarkers of antidepressant response. PMID: 23530732 [PubMed - as supplied by publisher] (Source: The World Journal of Biological Psychiatry)
Source: The World Journal of Biological Psychiatry - March 26, 2013 Category: Psychiatry Authors: Mamdani F, Berlim MT, Beaulieu MM, Turecki G Tags: World J Biol Psychiatry Source Type: research

Prescription of drugs with potential adverse effects on cardiac conduction in Parkinson's disease
Conclusions: Combination therapy and comorbidity relevant to cardiac QT prolongation are common in patients with Parkinson's disease. Strategies to reduce the proportion of patients at risk from iatrogenic adverse cardiac events are warranted. (Source: Parkinsonism and Related Disorders)
Source: Parkinsonism and Related Disorders - March 25, 2013 Category: Neurology Authors: Naveed M. Malek, Katherine A. Grosset, David Stewart, Graeme J.A. Macphee, Donald G. Grosset Tags: Papers Source Type: research

Additive Effects of 5-HTTLPR (Serotonin Transporter) and Tryptophan Hydroxylase 2 G-703T Gene Polymorphisms on the Clinical Response to Citalopram among Children and Adolescents with Depression and Anxiety Disorders
Journal of Child and Adolescent Psychopharmacology Mar 2013, Vol. 23, No. 2: 117-122. (Source: Journal of Child and Adolescent Psychopharmacology)
Source: Journal of Child and Adolescent Psychopharmacology - March 19, 2013 Category: Pediatrics Tags: article Source Type: research

Constitutively active 5-HT2/{alpha}1 receptors facilitate muscle spasms after human spinal cord injury
In this study we sought evidence for a similar role of constitutive monoamine receptor activity in the development of spasticity in human spinal cord injury. In chronically injured participants with partially preserved sensory and motor function, the serotonin reuptake inhibitor citalopram facilitated long-lasting reflex responses (spasms) previously shown to be mediated by CaPICs, suggesting that in incomplete spinal cord injury, functional descending sources of monoamines are present to activate monoamine receptors below the lesion. However, in participants with motor or motor/sensory complete injuries, the inverse agoni...
Source: Journal of Neurophysiology - March 15, 2013 Category: Neurology Authors: D'Amico, J. M., Murray, K. C., Li, Y., Chan, K. M., Finlay, M. G., Bennett, D. J., Gorassini, M. A. Tags: Articles Source Type: research

Selective serotonin reuptake inhibitors reduce P2Y12 receptor-mediated amplification of platelet aggregation
Abstract: Selective serotonin reuptake inhibitors (SSRIs) have been reported to reduce platelet aggregation induced by ADP. ADP induces platelet aggregation through two purinergic receptors P2Y1 and P2Y12. We characterized the inhibitory properties of SSRIs on ADP-induced platelet aggregation and investigated the effects of SSRIs on the signaling pathways downstream of P2Y1 and P2Y12 receptors. Specific antagonists were used to evaluate which purinergic receptor-mediated aggregation was influenced by SSRIs. The primary phase of ADP-induced aggregation was not inhibited by citalopram. Citalopram failed to influence ADP-indu...
Source: Thrombosis Research - March 14, 2013 Category: Hematology Authors: Yu-Lun Tseng, Meng-Ling Chiang, Hsien-Yuan Lane, Kuan-Pin Su, Yu-Chen Lai Tags: Platelets and Cell Biology Source Type: research

Treatment of multiple distressing spontaneous orgasms with citalopram and their re-emergence following discontinuation of prolonged use of citalopram in an adult female survivor of child sexual abuse.
Authors: Vohra A Abstract Serotonin reuptake inhibitors-induced orgasmic dysfunctions including spontaneous orgasms have been reported in women. Spontaneous orgasm is experiencing orgasm in the absence of sexual sensory stimulation. A woman with sexual abuse in her childhood who later developed distressing spontaneous orgasms is discussed. She stopped experiencing these orgasms with citalopram. However the orgasms soon re-emerged following the abrupt discontinuation of prolonged use of citalopram but disappeared again once the citalopram was re-introduced. To the best of the author's knowledge the therapeutic effec...
Source: Indian Journal of Psychiatry - March 9, 2013 Category: Psychiatry Tags: Indian J Psychiatry Source Type: research

Cost-utility of selective serotonin reuptake inhibitors for depression in primary care in Catalonia.
CONCLUSION: Fluoxetine seems to be a better cost-utility SSRI option for treating depressive disorders in PC. PMID: 17087814 [PubMed - indexed for MEDLINE] (Source: Acta Psychiatrica Scandinavica Supplementum)
Source: Acta Psychiatrica Scandinavica Supplementum - March 9, 2013 Category: Psychiatry Tags: Acta Psychiatr Scand Suppl Source Type: research

Comparative safety of selective serotonin reuptake inhibitors among pediatric users with respect to adverse cardiac events
This study aims to perform a comparative safety study assessing the risk of ventricular arrhythmia, cardiac arrest, or sudden death among pediatric selective serotonin reuptake inhibitor (SSRI) users. MethodsUsing US claims data from 1997 to 2009, new pediatric (age 
Source: Pharmacoepidemiology and Drug Safety - March 4, 2013 Category: Drugs & Pharmacology Authors: Angela S. Czaja, Robert J. Valuck, Heather D. Anderson Tags: Original Report Source Type: research

Citalopram: Hyperkinetic delirium in an elderly patient: case report
(Source: Reactions)
Source: Reactions - February 26, 2013 Category: Drugs & Pharmacology Tags: Short communication Source Type: research